Betacellulin induces increased retinal vascular permeability in mice

PLoS ONE

Volumn 5, Issue 10, 2010, Pages

  Anand Apte, Bela ^a   Ebrahem, Quteba ^a   Cutler, Alecia ^a   Farage, Eric ^a   Sugimoto, Masahiko ^a   Hollyfield, Joe ^a   Folkman, Judah ^b  

^a CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAM10 ENDOPEPTIDASE; BETACELLULIN; GLUCOSE; SIGNAL PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL PERMEABILITY; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC RETINOPATHY; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; NONHUMAN; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; RETINA BLOOD VESSEL; WESTERN BLOTTING; ANIMAL; BLOOD RETINA BARRIER; C57BL MOUSE; CAPILLARY PERMEABILITY; DRUG EFFECT; MOUSE; POLYACRYLAMIDE GEL ELECTROPHORESIS;

MUS;

ANIMALS; BLOOD-RETINAL BARRIER; CAPILLARY PERMEABILITY; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, INBRED C57BL; RETINAL VESSELS;

EID: 78149441695     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0013444     Document Type: Article

References (41)

1. Group TDCacTR (1993) Implications of the Diabetes Control and Complications Trial. American Diabetes Association. Diabetes 42: 1555-1558.
2. Keenan HA, Costacou T, Sun JK, Doria A, Cavellerano J, et al. (2007) Clinical factors associated with resistance to microvascular complications in diabetic patients of extreme disease duration: the 50-year medalist study. Diabetes Care 30: 1995-1997.
3. Wong TY, Liew G, Tapp RJ, Schmidt MI, Wang JJ, et al. (2008) Relation between fasting glucose and retinopathy for diagnosis of diabetes: three population-based cross-sectional studies. Lancet 371: 736-743.
4. Group AS, Group AES, Chew EY, Ambrosius WT, Davis D, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 363: 233-244.
5. Group. TDCaCTR (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 329: 977-986.
6. Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 376: 419-430.
7. Shing Y, Christofori G, Hanahan D, Ono Y, Sasada R, et al. (1993) Betacellulin: a mitogen from pancreatic beta cell tumors. Science 259: 1604-1607.
8. Riese DJ, 2nd, Bermingham Y, van Raaij TM, Buckley S, Plowman GD, et al. (1996) Betacellulin activates the epidermal growth factor receptor and erbB-4, and induces cellular response patterns distinct from those stimulated by epidermal growth factor or neuregulin-beta. Oncogene 12: 345-353.
9. Riese DJ, Kim ED, Elenius K, Buckley S, Klagsbrun M, et al. (1996) The epidermal growth factor receptor couples transforming growth factor-alpha, heparin-binding epidermal growth factor-like factor, and amphiregulin to Neu, ErbB-3, and ErbB-4. J Biol Chem 271: 20047-20052.
10. Watanabe T, Shintani A, Nakata M, Shing Y, Folkman J, et al. (1994) Recombinant human betacellulin. Molecular structure, biological activities, and receptor interaction. J Biol Chem 269: 9966-9973.
11. Li L, Seno M, Yamada H, Kojima I (2003) Betacellulin improves glucose metabolism by promoting conversion of intraislet precursor cells to beta-cells in streptozotocin-treated mice. Am J Physiol Endocrinol Metab 285: E577-583.
12. Li L, Yi Z, Seno M, Kojima I (2004) Activin A and betacellulin: effect on regeneration of pancreatic beta-cells in neonatal streptozotocin-treated rats. Diabetes 53: 608-615.
13. Seno M, Tada H, Kosaka M, Sasada R, Igarashi K, et al. (1996) Human betacellulin, a member of the EGF family dominantly expressed in pancreas and small intestine, is fully active in a monomeric form. Growth Factors 13: 181-191.
14. Mashima H, Ohnishi H, Wakabayashi K, Mine T, Miyagawa J, et al. (1996) Betacellulin and activin A coordinately convert amylase-secreting pancreatic AR42J cells into insulin-secreting cells. J Clin Invest 97: 1647-1654.
15. Miyagawa J, Hanafusa O, Sasada R, Yamamoto K, Igarashi K, et al. (1999) Immunohistochemical localization of betacellulin, a new member of the EGF family, in normal human pancreas and islet tumor cells. Endocr J 46: 755-764.
16. Yamamoto K, Miyagawa J, Waguri M, Sasada R, Igarashi K, et al. (2000) Recombinant human betacellulin promotes the neogenesis of beta-cells and ameliorates glucose intolerance in mice with diabetes induced by selective alloxan perfusion. Diabetes 49: 2021-2027.
17. Xu Q, Qaum T, Adamis AP (2001) Sensitive blood-retinal barrier breakdown quantitation using Evans blue. Invest Ophthalmol Vis Sci 42: 789-794.
18. Qaum T, Xu Q, Joussen AM, Clemens MW, Qin W, et al. (2001) VEGFinitiated blood-retinal barrier breakdown in early diabetes. Invest Ophthalmol Vis Sci 42: 2408-2413.
19. Holbro T, Hynes NE (2004) ErbB receptors: directing key signaling networks throughout life. Annu Rev Pharmacol Toxicol 44: 195-217.
20. Sahin U, Weskamp G, Kelly K, Zhou HM, Higashiyama S, et al. (2004) Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. J Cell Biol 164: 769-779.
21. Sanderson MP, Erickson SN, Gough PJ, Garton KJ, Wille PT, et al. (2005) ADAM10 mediates ectodomain shedding of the betacellulin precursor activated by p-aminophenylmercuric acetate and extracellular calcium influx. J Biol Chem 280: 1826-1837.
22. Aiello LP, Gardner TW, King GL, Blankenship G, Cavallerano JD, et al. (1998) Diabetic retinopathy. Diabetes Care 21: 143-156.
23. Johansen J, Sjolie AK, Elbol P, Eshoj O (1994) The relation between retinopathy and albumin excretion rate in insulin-dependent diabetes mellitus. From the Funen County Epidemiology of Type 1 Diabetes Complications Survey. Acta Ophthalmol (Copenh) 72: 347-351.
24. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL (1984) The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 102: 520-526.
25. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL (1984) The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 102: 527-532.
26. Orchard TJ, Dorman JS, Maser RE, Becker DJ, Drash AL, et al. (1990) Prevalence of complications in IDDM by sex and duration. Pittsburgh Epidemiology of Diabetes Complications Study II. Diabetes 39: 1116-1124.
27. Funatsu H, Yamashita H, Ikeda T, Mimura T, Eguchi S, et al. (2003) Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology 110: 1690-1696.
28. Arjamaa O, Nikinmaa M (2006) Oxygen-dependent diseases in the retina: role of hypoxia-inducible factors. Exp Eye Res 83: 473-483.
29. Manzoni P, Maestri A, Gomirato G, Takagi H, Watanabe D, et al. (2005) Erythropoietin as a retinal angiogenic factor. N Engl J Med 353: 2190-2191. author reply 2190-2191.
30. Aiello LP (2008) Targeting intraocular neovascularization and edema-one drop at a time. N Engl J Med 359: 967-969.
31. Gao BB, Chen X, Timothy N, Aiello LP, Feener EP (2008) Characterization of the vitreous proteome in diabetes without diabetic retinopathy and diabetes with proliferative diabetic retinopathy. J Proteome Res 7: 2516-2525.
32. Gao BB, Clermont A, Rook S, Fonda SJ, Srinivasan VJ, et al. (2007) Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation. Nat Med 13: 181-188.
33. Tong Z, Yang Z, Patel S, Chen H, Gibbs D, et al. (2008) Promoter polymorphism of the erythropoietin gene in severe diabetic eye and kidney complications. Proc Natl Acad Sci U S A 105: 6998-7003.
34. Watanabe D, Suzuma K, Matsui S, Kurimoto M, Kiryu J, et al. (2005) Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med 353: 782-792.
35. Ponnuchamy B, Khalil RA (2008) Role of ADAMs in endothelial cell permeability: cadherin shedding and leukocyte rolling. Circ Res 102: 1139-1142.
36. Schulz B, Pruessmeyer J, Maretzky T, Ludwig A, Blobel CP, et al. (2008) ADAM10 regulates endothelial permeability and T-Cell transmigration by proteolysis of vascular endothelial cadherin. Circ Res 102: 1192-1201.
37. Blobel CP (2005) ADAMs: key components in EGFR signalling and development. Nat Rev Mol Cell Biol 6: 32-43.
38. Sahin U, Blobel CP (2007) Ectodomain shedding of the EGF-receptor ligand epigen is mediated by ADAM17. FEBS Lett 581: 41-44.
39. Sanderson MP, Abbott CA, Tada H, Seno M, Dempsey PJ, et al. (2006) Hydrogen peroxide and endothelin-1 are novel activators of betacellulin ectodomain shedding. J Cell Biochem 99: 609-623.
40. Kojima H, Fujimiya M, Matsumura K, Younan P, Imaeda H, et al. (2003) NeuroD-betacellulin gene therapy induces islet neogenesis in the liver and reverses diabetes in mice. Nat Med 9: 596-603.
41. Antonetti DA, Barber AJ, Bronson SK, Freeman WM, Gardner TW, et al. (2006) Diabetic retinopathy: seeing beyond glucose-induced microvascular disease. Diabetes 55: 2401-2411.